UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2018 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or other jurisdiction of in ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2018 Earnings Conference Call March 28, 2019 4:30 PM ET Corporate Participants AJ Bergmann - Chief Financial Officer Linda Marbán - President & Chief Executive Officer Conference Call Participants Jason McCarthy - Maxim Group Joe Pantginis - H.C. Wainwright Tim Chiang - BTIG Operator Welcome to Capricorn Therapeutics Fourth Quarter and Full Year 2018 Conference Call. My name is Morin and I'll be your operator for today's call. At this time all participants are in ...